Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management

Autor: Anna J. Lomax, Jennifer Lim, Robert Cheng, Arianne Sweeting, Patricia Lowe, Neil McGill, Nicholas Shackel, Elizabeth L. Chua, Catriona McNeil

Publikováno v: Journal of Skin Cancer, Vol 2018 (2018)

Immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) are a standard of care for advanced melanoma. Novel toxicities comprise immune-related adverse events (irAE). With increasing use, irAE require recognition, practical management stra

Externí odkaz: https://doaj.org/article/6a6c7629b3c04ae4a1a5ce60b738c779

Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician

Autor: Anna J. Lomax, Catriona M. McNeil

Publikováno v: Emergency Medicine Australasia. 29:245-251

When a patient receiving anti-cancer treatment presents acutely unwell, an understanding of associated side effects of their therapy is critical. This review will discuss the approach to patients receiving anti-cancer treatment with immunotherapy pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3159fc561a6d7e8a14f0d96131d69aed
https://doi.org/10.1111/1742-6723.12718

Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab

Autor: Anna J. Lomax, Catriona M. McNeil, Sunaina Anand, Ludi Ge, Patricia Lowe

Publikováno v: Australasian Journal of Dermatology. 57:333-335

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b782a4477d0f96ff768a4395becabefc
https://doi.org/10.1111/ajd.12484

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis

Autor: Sebastian van Hal, Catriona M. McNeil, Helen M. McGuire, Deme Karikios, Jane Hollingsworth, Clara J. Choi, Sandeep K. Gupta, Neil McGill, Peter Hersey, Barbara Fazekas de St Groth, Haewon Kim, Kerwin F. Shannon, Urszula Carr, Anna J. Lomax, Anne Crotty

Publikováno v: International journal of rheumatic diseases. 20(9)

Aim Sarcoidosis is a multisystem granulomatous disease. This condition has a documented association with the diagnosis of melanoma and can be induced in melanoma patients receiving anti-neoplastic therapy. We evaluated a case series of melanoma patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34c5c428e37428f1cad8317c87608a2a
https://pubmed.ncbi.nlm.nih.gov/28480561

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Autor: Mohammed Islam, Michael B. Jameson, Jonathan Cebon, Georgina V. Long, Anna J. Lomax, Alexander Guminski, Babak Tamjid, Wen-Jen Hwu, Richard F. Kefford, John A. Thompson, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas, Xinxin Shu, Matteo S. Carlino, Alexander M. Menzies, Archana Srivastava, Benjamin Y. Kong, Catriona M. McNeil, Victoria Atkinson, Bernie M. Fitzharris, Andrew G. Hill, F. Stephen Hodi, Michael B. Atkins

Publikováno v: Long, GV; Atkinson, V; Cebon, JS; Jameson, MB; Fitzharris, BM; McNeil, CM; et al.(2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202-1210. doi: 10.1016/S1470-2045(17)30428-X. UCLA: Retrieved from: http://www.escholarship.org/uc/item/0fq0574t
The Lancet. Oncology, vol 18, iss 9

© 2017 Elsevier Ltd Background Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8cbcb0612e041d928b60376b1140cbc
https://pubmed.ncbi.nlm.nih.gov/28729152